London
· Delayed Price · Currency is GBP · Price in GBXShield Therapeutics Statistics
Total Valuation
Shield Therapeutics has a market cap or net worth of GBP 36.76 million. The enterprise value is 46.15 million.
| Market Cap | 36.76M |
| Enterprise Value | 46.15M |
Important Dates
The last earnings date was Monday, September 16, 2024.
| Earnings Date | Sep 16, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Shield Therapeutics has 782.06 million shares outstanding. The number of shares has increased by 59.90% in one year.
| Shares Outstanding | 782.06M |
| Shares Change (YoY) | +59.90% |
| Shares Change (QoQ) | +5.37% |
| Owned by Insiders (%) | 2.73% |
| Owned by Institutions (%) | 32.44% |
| Float | 408.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.11 |
| PB Ratio | 85.96 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.61 |
| EV / Sales | 2.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.79 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 36.91.
| Current Ratio | 1.05 |
| Quick Ratio | 0.90 |
| Debt / Equity | 36.91 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.96 |
| Interest Coverage | -16.41 |
Financial Efficiency
Return on equity (ROE) is -261.66% and return on invested capital (ROIC) is -79.25%.
| Return on Equity (ROE) | -261.66% |
| Return on Assets (ROA) | -47.85% |
| Return on Capital (ROIC) | -79.25% |
| Revenue Per Employee | 232,763 |
| Profits Per Employee | -392,015 |
| Employee Count | 73 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 4.06 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.88% |
| 50-Day Moving Average | 4.15 |
| 200-Day Moving Average | 3.34 |
| Relative Strength Index (RSI) | 58.49 |
| Average Volume (20 Days) | 2,302,194 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shield Therapeutics had revenue of GBP 16.99 million and -28.62 million in losses. Loss per share was -0.04.
| Revenue | 16.99M |
| Gross Profit | 6.19M |
| Operating Income | -26.78M |
| Pretax Income | -28.53M |
| Net Income | -28.62M |
| EBITDA | -26.83M |
| EBIT | -26.78M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 6.41 million in cash and 15.80 million in debt, giving a net cash position of -9.39 million or -0.01 per share.
| Cash & Cash Equivalents | 6.41M |
| Total Debt | 15.80M |
| Net Cash | -9.39M |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | 428,077 |
| Book Value Per Share | 0.00 |
| Working Capital | 1.02M |
Cash Flow
In the last 12 months, operating cash flow was -16.45 million and capital expenditures -75,171, giving a free cash flow of -16.53 million.
| Operating Cash Flow | -16.45M |
| Capital Expenditures | -75,171 |
| Free Cash Flow | -16.53M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 36.44%, with operating and profit margins of -157.62% and -168.42%.
| Gross Margin | 36.44% |
| Operating Margin | -157.62% |
| Pretax Margin | -167.93% |
| Profit Margin | -168.42% |
| EBITDA Margin | -157.89% |
| EBIT Margin | -157.62% |
| FCF Margin | -97.28% |
Dividends & Yields
Shield Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -59.90% |
| Shareholder Yield | -59.90% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Shield Therapeutics has an Altman Z-Score of -8.63. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.63 |
| Piotroski F-Score | n/a |